133 related articles for article (PubMed ID: 17229460)
1. The diagnostic value of PET/CT for primary ovarian cancer--a prospective study.
Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
Gynecol Oncol; 2007 Apr; 105(1):145-9. PubMed ID: 17229460
[TBL] [Abstract][Full Text] [Related]
2. Does the use of diagnostic PET/CT cause stage migration in patients with primary advanced ovarian cancer?
Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
Gynecol Oncol; 2010 Mar; 116(3):395-8. PubMed ID: 20042226
[TBL] [Abstract][Full Text] [Related]
3. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography.
Yamamoto Y; Oguri H; Yamada R; Maeda N; Kohsaki S; Fukaya T
Int J Gynaecol Obstet; 2008 Aug; 102(2):124-7. PubMed ID: 18423470
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI.
Nam EJ; Yun MJ; Oh YT; Kim JW; Kim JH; Kim S; Jung YW; Kim SW; Kim YT
Gynecol Oncol; 2010 Mar; 116(3):389-94. PubMed ID: 19926121
[TBL] [Abstract][Full Text] [Related]
5. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography--a prospective study.
Risum S; Høgdall C; Loft A; Berthelsen AK; Høgdall E; Nedergaard L; Lundvall L; Engelholm SA
Gynecol Oncol; 2008 Feb; 108(2):265-70. PubMed ID: 18055006
[TBL] [Abstract][Full Text] [Related]
6. PET/CT in the staging of patients with a pelvic mass suspicious for ovarian cancer.
Dauwen H; Van Calster B; Deroose CM; Op de Beeck K; Amant F; Neven P; Berteloot P; Leunen K; Timmerman D; Vergote I
Gynecol Oncol; 2013 Dec; 131(3):694-700. PubMed ID: 23988417
[TBL] [Abstract][Full Text] [Related]
7. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
Tsuboyama T; Tatsumi M; Onishi H; Nakamoto A; Kim T; Hori M; Sakane M; Hori Y; Morii E; Hatazawa J; Tomiyama N
Invest Radiol; 2014 Aug; 49(8):524-31. PubMed ID: 24637584
[TBL] [Abstract][Full Text] [Related]
8. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass.
Håkansson F; Høgdall EV; Nedergaard L; Lundvall L; Engelholm SA; Pedersen AT; Hartwell D; Høgdall C;
Acta Obstet Gynecol Scand; 2012 Apr; 91(4):496-502. PubMed ID: 22229703
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology.
Castellucci P; Perrone AM; Picchio M; Ghi T; Farsad M; Nanni C; Messa C; Meriggiola MC; Pelusi G; Al-Nahhas A; Rubello D; Fazio F; Fanti S
Nucl Med Commun; 2007 Aug; 28(8):589-95. PubMed ID: 17625380
[TBL] [Abstract][Full Text] [Related]
10. Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.
Rubini G; Altini C; Notaristefano A; Merenda N; Rubini D; Ianora AA; Asabella AN
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):22-7. PubMed ID: 23948509
[TBL] [Abstract][Full Text] [Related]
11. Utility of PET/CT in the diagnosis of recurrent ovarian cancer depending on CA 125 serum level.
Fularz M; Adamiak P; Czepczyński R; Jarząbek-Bielecka G; Rewers A; Kędzia W; Ruchała M
Nuklearmedizin; 2015; 54(4):158-62. PubMed ID: 26076719
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET-CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation.
Kuyumcuoğlu U; Guzel AI; Celik Y; Erdemoğlu M; Komek H
Ginekol Pol; 2011 Aug; 82(8):602-6. PubMed ID: 21957605
[TBL] [Abstract][Full Text] [Related]
13. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer.
Yen RF; Sun SS; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(5):3691-4. PubMed ID: 11848544
[TBL] [Abstract][Full Text] [Related]
14. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
[TBL] [Abstract][Full Text] [Related]
15. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT.
Kim CK; Park BK; Choi JY; Kim BG; Han H
J Comput Assist Tomogr; 2007; 31(6):868-75. PubMed ID: 18043348
[TBL] [Abstract][Full Text] [Related]
16. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
17. Role of FDG PET-CT in asymptomatic epithelial ovarian cancer with rising serum CA-125: a pilot study.
Ghosh J; Thulkar S; Kumar R; Malhotra A; Kumar A; Kumar L
Natl Med J India; 2013; 26(6):327-31. PubMed ID: 25073988
[TBL] [Abstract][Full Text] [Related]
18. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass.
Dora SK; Dandapat AB; Pande B; Hota JP
J Ovarian Res; 2017 Aug; 10(1):55. PubMed ID: 28806987
[TBL] [Abstract][Full Text] [Related]
19. Combined PET/CT for detecting recurrent ovarian cancer limited to retroperitoneal lymph nodes.
Bristow RE; Giuntoli RL; Pannu HK; Schulick RD; Fishman EK; Wahl RL
Gynecol Oncol; 2005 Nov; 99(2):294-300. PubMed ID: 16051330
[TBL] [Abstract][Full Text] [Related]
20. Impact of [18F]-2-fluorodeoxyglucose-positron emission tomography/computed tomography on previously untreated head and neck cancer patients.
Fleming AJ; Smith SP; Paul CM; Hall NC; Daly BT; Agrawal A; Schuller DE
Laryngoscope; 2007 Jul; 117(7):1173-9. PubMed ID: 17603315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
